Real-world study finds patients switching from obesity shots to Novo’s daily Wegovy pill lose 4.1% in three months
AI Market Summary
Real-world data presented at EASD suggests patients switching from injectable obesity therapies to Novo's oral semaglutide (Wegovy pill) achieved meaningful short-term weight loss and improved obesity classification, supporting adherence and efficacy concerns around pills. With oral therapies rising to roughly a third of U.S. obesity prescriptions and Novo capturing most new oral starts, the findings strengthen Novo's positioning versus Lilly in the fast-growing GLP-1 market.
Impact level
● Medium
Affected assets
NCSKNVO2USD/USDT+1.35%
AI Insight · NCSKNVO2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
A real-world study found patients who moved from injectable obesity treatments to a daily oral semaglutide pill lost an average of 4.1% of body weight over three months, or 4.0 kg, from a 221.6-pound baseline. The share classified as clinically obese fell to 65.5% from 87.1% over the same period. Nearly 41% of participants lost at least 5% of their body weight. The findings were presented at a medical conference as Novo Nordisk pushes an oral obesity option amid competition from Eli Lilly.
